Products
Ensomafusp Alfa Biosimilar Bispecific Biologic (CD19 × 4-1BB) for Research
Cat No.: GMP-Bios-INN-836
Pre-made Ensomafusp Alfa benchmark antibody (Bispecific, anti-CD19;TNFRSF9 therapeutic antibody, Anti-B4/CVID3;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-836-1mg | 1mg | |
| GMP-Bios-INN-836-10mg | 10mg | |
| GMP-Bios-INN-836-100mg | 100mg | |
| GMP-Bios-INN-836-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ensomafusp Alfa Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibody |
| INN Name | Ensomafusp Alfa |
| Target | CD19;TNFRSF9 |
| Format | Bispecific |
| Derivation | |
| Species Reactivity | |
| CH1 Isotype | |
| VD LC | |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech |
